3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
5
Stomatitis
3
Head and Neck Neoplasms
3
Fatigue
3
Colorectal Neoplasms
3
Pain
2
Multiple Myeloma
2
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Ulcer
1
Trauma, Nervous System
1
Spondylitis, Ankylosing
1
Skin Neoplasms
1
Schwannomatosis
1
Rectal Neoplasms
1
Psoriasis
1
Pleural Effusion, Malignant
1
Pancreatic Cyst
1
Ovarian Neoplasms
1
Non-functioning Pituitary Adenoma
1
Neurofibromatosis 1
1
Neurilemmoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Mesothelioma
1
Malignant Neoplasm of Colorectum
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
Saline Solution
×
Clear all
NCT05493800
2024-05-29
Capella
MitoImmune Therapeutics
Phase 2
Unknown
60 enrolled